Inhibrx

About:

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Website: http://inhibrx.com

Top Investors: RA Capital Management, Perceptive Advisors, Viking Global Investors, Lilly Asia Ventures, TCG Crossover

Description:

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X.